BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY
Identifieur interne : 000329 ( Istex/Corpus ); précédent : 000328; suivant : 000330BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY
Auteurs : Graeme Morgan ; Derek BergSource :
- Australian and New Zealand Journal of Surgery [ 0004-8682 ] ; 1989-02.
Abstract
Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use. The probability of local relapse can be determined by careful evaluation of the histological features of the primary tumour, the absolute number of involved axillary nodes and the type and extent of the surgery performed. Using these data, patients can be divided into a relatively low risk group who probably do not require radiotherapy and a group at significant risk of relapse who, even with adjuvant systemic therapy, are likely to benefit from postoperative radiotherapy. Despite the often‐repeated view to the contrary, radiotherapy is more effective in the locoregional control of breast cancer if given postoperatively than if withheld until tumour relapse occurs. Radiotherapy at the time of relapse provides long‐term control in only 40–55% of patients. This results in significant morbidity from uncontrolled local disease in the one‐third of patients who survive 5 years and the one‐quarter of patients who survive 10 years from the time of local relapse. This paper outlines the rationale and indications for the use of radiotherapy in improving locoregional control in breast cancer.
Url:
DOI: 10.1111/j.1445-2197.1989.tb01478.x
Links to Exploration step
ISTEX:071A030DF3A7EEA1A91F2BCB594CE8337628E3A2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title><author><name sortKey="Morgan, Graeme" sort="Morgan, Graeme" uniqKey="Morgan G" first="Graeme" last="Morgan">Graeme Morgan</name><affiliation><mods:affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.</mods:affiliation></affiliation></author><author><name sortKey="Berg, Derek" sort="Berg, Derek" uniqKey="Berg D" first="Derek" last="Berg">Derek Berg</name><affiliation><mods:affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:071A030DF3A7EEA1A91F2BCB594CE8337628E3A2</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1111/j.1445-2197.1989.tb01478.x</idno><idno type="url">https://api.istex.fr/document/071A030DF3A7EEA1A91F2BCB594CE8337628E3A2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000329</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000329</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title><author><name sortKey="Morgan, Graeme" sort="Morgan, Graeme" uniqKey="Morgan G" first="Graeme" last="Morgan">Graeme Morgan</name><affiliation><mods:affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.</mods:affiliation></affiliation></author><author><name sortKey="Berg, Derek" sort="Berg, Derek" uniqKey="Berg D" first="Derek" last="Berg">Derek Berg</name><affiliation><mods:affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Australian and New Zealand Journal of Surgery</title><title level="j" type="alt">AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY</title><idno type="ISSN">0004-8682</idno><idno type="eISSN">1445-2197</idno><imprint><biblScope unit="vol">59</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="105">105</biblScope><biblScope unit="page" to="113">113</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-02">1989-02</date></imprint><idno type="ISSN">0004-8682</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0004-8682</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use. The probability of local relapse can be determined by careful evaluation of the histological features of the primary tumour, the absolute number of involved axillary nodes and the type and extent of the surgery performed. Using these data, patients can be divided into a relatively low risk group who probably do not require radiotherapy and a group at significant risk of relapse who, even with adjuvant systemic therapy, are likely to benefit from postoperative radiotherapy. Despite the often‐repeated view to the contrary, radiotherapy is more effective in the locoregional control of breast cancer if given postoperatively than if withheld until tumour relapse occurs. Radiotherapy at the time of relapse provides long‐term control in only 40–55% of patients. This results in significant morbidity from uncontrolled local disease in the one‐third of patients who survive 5 years and the one‐quarter of patients who survive 10 years from the time of local relapse. This paper outlines the rationale and indications for the use of radiotherapy in improving locoregional control in breast cancer.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>radiotherapy</json:string><json:string>node</json:string><json:string>axillary</json:string><json:string>relapse</json:string><json:string>breast cancer</json:string><json:string>mastectomy</json:string><json:string>adjuvant</json:string><json:string>locoregional</json:string><json:string>tumour</json:string><json:string>axilla</json:string><json:string>postoperative</json:string><json:string>chemotherapy</json:string><json:string>recurrence</json:string><json:string>histological</json:string><json:string>surg</json:string><json:string>postoperative radiotherapy</json:string><json:string>tamoxifen</json:string><json:string>radical mastectomy</json:string><json:string>histologically</json:string><json:string>locoregional relapse</json:string><json:string>oncol</json:string><json:string>local recurrence</json:string><json:string>adjuvant chemotherapy</json:string><json:string>axillary nodes</json:string><json:string>phys</json:string><json:string>extranodal</json:string><json:string>local relapse</json:string><json:string>early breast cancer</json:string><json:string>significant risk</json:string><json:string>total mastectomy</json:string><json:string>carcinoma</json:string><json:string>local control</json:string><json:string>locoregional control</json:string><json:string>simple mastectomy</json:string><json:string>overall survival</json:string><json:string>axillary node involvement</json:string><json:string>negative axilla</json:string><json:string>primary tumour</json:string><json:string>axillary dissection</json:string><json:string>positive nodes</json:string><json:string>extranodal disease</json:string><json:string>relapse rate</json:string><json:string>first failure</json:string><json:string>local disease</json:string><json:string>breast</json:string><json:string>axillary sampling</json:string><json:string>absolute number</json:string><json:string>chest wall recurrence</json:string><json:string>medial quadrant tumour</json:string><json:string>partial mastectomy</json:string><json:string>primary breast cancer</json:string><json:string>local excision</json:string><json:string>axillary clearance</json:string><json:string>adjuvant tamoxifen</json:string><json:string>survival rate</json:string><json:string>chest wall irradiation</json:string><json:string>histological features</json:string><json:string>tumour grade</json:string><json:string>little doubt</json:string><json:string>dissection</json:string></teeft></keywords><author><json:item><name>Graeme Morgan mrcp (uk), fracr</name><affiliations><json:string>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</json:string><json:string>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.</json:string></affiliations></json:item><json:item><name>Derek Berg fracs, fracr.</name><affiliations><json:string>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>adjuvant chemotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>breast cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>radiotherapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tamoxifen.</value></json:item></subject><articleId><json:string>ANS105</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use. The probability of local relapse can be determined by careful evaluation of the histological features of the primary tumour, the absolute number of involved axillary nodes and the type and extent of the surgery performed. Using these data, patients can be divided into a relatively low risk group who probably do not require radiotherapy and a group at significant risk of relapse who, even with adjuvant systemic therapy, are likely to benefit from postoperative radiotherapy. Despite the often‐repeated view to the contrary, radiotherapy is more effective in the locoregional control of breast cancer if given postoperatively than if withheld until tumour relapse occurs. Radiotherapy at the time of relapse provides long‐term control in only 40–55% of patients. This results in significant morbidity from uncontrolled local disease in the one‐third of patients who survive 5 years and the one‐quarter of patients who survive 10 years from the time of local relapse. This paper outlines the rationale and indications for the use of radiotherapy in improving locoregional control in breast cancer.</abstract><qualityIndicators><score>7.244</score><pdfVersion>1.3</pdfVersion><pdfPageSize>511.44 x 723.84 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1218</abstractCharCount><pdfWordCount>5533</pdfWordCount><pdfCharCount>34579</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>187</abstractWordCount></qualityIndicators><title>BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title><genre><json:string>review-article</json:string></genre><host><title>Australian and New Zealand Journal of Surgery</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1445-2197a</json:string></doi><issn><json:string>0004-8682</json:string></issn><eissn><json:string>1445-2197</json:string></eissn><publisherId><json:string>ANS</json:string></publisherId><volume>59</volume><issue>2</issue><pages><first>105</first><last>113</last><total>9</total></pages><genre><json:string>journal</json:string></genre></host><categories><wos></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>surgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1111/j.1445-2197.1989.tb01478.x</json:string></doi><id>071A030DF3A7EEA1A91F2BCB594CE8337628E3A2</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/071A030DF3A7EEA1A91F2BCB594CE8337628E3A2/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/071A030DF3A7EEA1A91F2BCB594CE8337628E3A2/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/071A030DF3A7EEA1A91F2BCB594CE8337628E3A2/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title></titleStmt><publicationStmt><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-02"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Graeme</forename><surname>Morgan</surname><roleName type="degree">mrcp (uk), fracr</roleName></persName><affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</affiliation><affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Derek</forename><surname>Berg</surname><roleName type="degree">fracs, fracr.</roleName></persName><affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</affiliation></author><idno type="istex">071A030DF3A7EEA1A91F2BCB594CE8337628E3A2</idno><idno type="DOI">10.1111/j.1445-2197.1989.tb01478.x</idno><idno type="unit">ANS105</idno><idno type="toTypesetVersion">file:ANS.ANS105.pdf</idno></analytic><monogr><title level="j" type="main">Australian and New Zealand Journal of Surgery</title><title level="j" type="alt">AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY</title><idno type="pISSN">0004-8682</idno><idno type="eISSN">1445-2197</idno><idno type="book-DOI">10.1111/(ISSN)1445-2197a</idno><idno type="book-part-DOI">10.1111/ans.1989.59.issue-2</idno><idno type="product">ANS</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">59</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="105">105</biblScope><biblScope unit="page" to="113">113</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-02"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><p>Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use. The probability of local relapse can be determined by careful evaluation of the histological features of the primary tumour, the absolute number of involved axillary nodes and the type and extent of the surgery performed. Using these data, patients can be divided into a relatively low risk group who probably do not require radiotherapy and a group at significant risk of relapse who, even with adjuvant systemic therapy, are likely to benefit from postoperative radiotherapy. Despite the often‐repeated view to the contrary, radiotherapy is more effective in the locoregional control of breast cancer if given postoperatively than if withheld until tumour relapse occurs. Radiotherapy at the time of relapse provides long‐term control in only 40–55% of patients. This results in significant morbidity from uncontrolled local disease in the one‐third of patients who survive 5 years and the one‐quarter of patients who survive 10 years from the time of local relapse. This paper outlines the rationale and indications for the use of radiotherapy in improving locoregional control in breast cancer.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">adjuvant chemotherapy</term><term xml:id="k2">breast cancer</term><term xml:id="k3">radiotherapy</term><term xml:id="k4">tamoxifen.</term></keywords><classCode scheme="tocHeading1">Review Article</classCode></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/071A030DF3A7EEA1A91F2BCB594CE8337628E3A2/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1445-2197a</doi><issn type="print">0004-8682</issn><issn type="electronic">1445-2197</issn><idGroup><id type="product" value="ANS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY">Australian and New Zealand Journal of Surgery</title></titleGroup></publicationMeta><publicationMeta level="part" position="02102"><doi origin="wiley">10.1111/ans.1989.59.issue-2</doi><numberingGroup><numbering type="journalVolume" number="59">59</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="1989-02">February 1989</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="0010500" status="forIssue"><doi origin="wiley">10.1111/j.1445-2197.1989.tb01478.x</doi><idGroup><id type="unit" value="ANS105"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="tocHeading1">Review Article</title></titleGroup><eventGroup><event type="firstOnline" date="2008-01-21"></event><event type="publishedOnlineFinalForm" date="2010-06-14"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-01-21"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.27 mode:FullText source:HeaderRef result:HeaderRef" date="2010-11-22"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="105">105</numbering><numbering type="pageLast" number="113">113</numbering></numberingGroup><correspondenceTo>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANS.ANS105.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted for publication 20 July 1988.</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="67"></count><count type="linksCrossRef" number="3"></count></countGroup><titleGroup><title type="main">BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Graeme</givenNames><familyName>Morgan</familyName><degrees>mrcp (uk), fracr</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Derek</givenNames><familyName>Berg</familyName><degrees>fracs, fracr.</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="a1"><unparsedAffiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">adjuvant chemotherapy</keyword><keyword xml:id="k2">breast cancer</keyword><keyword xml:id="k3">radiotherapy</keyword><keyword xml:id="k4">tamoxifen.</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use. The probability of local relapse can be determined by careful evaluation of the histological features of the primary tumour, the absolute number of involved axillary nodes and the type and extent of the surgery performed. Using these data, patients can be divided into a relatively low risk group who probably do not require radiotherapy and a group at significant risk of relapse who, even with adjuvant systemic therapy, are likely to benefit from postoperative radiotherapy. Despite the often‐repeated view to the contrary, radiotherapy is more effective in the locoregional control of breast cancer if given postoperatively than if withheld until tumour relapse occurs. Radiotherapy at the time of relapse provides long‐term control in only 40–55% of patients. This results in significant morbidity from uncontrolled local disease in the one‐third of patients who survive 5 years and the one‐quarter of patients who survive 10 years from the time of local relapse. This paper outlines the rationale and indications for the use of radiotherapy in improving locoregional control in breast cancer.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY</title></titleInfo><name type="personal"><namePart type="given">Graeme</namePart><namePart type="family">Morgan</namePart><namePart type="termsOfAddress">mrcp (uk), fracr</namePart><affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</affiliation><affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW 2010, Australia.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Derek</namePart><namePart type="family">Berg</namePart><namePart type="termsOfAddress">fracs, fracr.</namePart><affiliation>Department of Radiation Oncology, St Vincent's Hospital, Darlinghurst, NSW</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1989-02</dateIssued><edition>Accepted for publication 20 July 1988.</edition><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">67</extent></physicalDescription><abstract lang="en">Although the role of radiotherapy in breast cancer is controversial, there are clearly defined indications for its use. The probability of local relapse can be determined by careful evaluation of the histological features of the primary tumour, the absolute number of involved axillary nodes and the type and extent of the surgery performed. Using these data, patients can be divided into a relatively low risk group who probably do not require radiotherapy and a group at significant risk of relapse who, even with adjuvant systemic therapy, are likely to benefit from postoperative radiotherapy. Despite the often‐repeated view to the contrary, radiotherapy is more effective in the locoregional control of breast cancer if given postoperatively than if withheld until tumour relapse occurs. Radiotherapy at the time of relapse provides long‐term control in only 40–55% of patients. This results in significant morbidity from uncontrolled local disease in the one‐third of patients who survive 5 years and the one‐quarter of patients who survive 10 years from the time of local relapse. This paper outlines the rationale and indications for the use of radiotherapy in improving locoregional control in breast cancer.</abstract><subject lang="en"><genre>keywords</genre><topic>adjuvant chemotherapy</topic><topic>breast cancer</topic><topic>radiotherapy</topic><topic>tamoxifen.</topic></subject><relatedItem type="host"><titleInfo><title>Australian and New Zealand Journal of Surgery</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0004-8682</identifier><identifier type="eISSN">1445-2197</identifier><identifier type="DOI">10.1111/(ISSN)1445-2197a</identifier><identifier type="PublisherID">ANS</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>105</start><end>113</end><total>9</total></extent></part></relatedItem><identifier type="istex">071A030DF3A7EEA1A91F2BCB594CE8337628E3A2</identifier><identifier type="DOI">10.1111/j.1445-2197.1989.tb01478.x</identifier><identifier type="ArticleID">ANS105</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000329 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000329 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:071A030DF3A7EEA1A91F2BCB594CE8337628E3A2
|texte= BREAST CANCER: THE ROLE OF POSTOPERATIVE RADIOTHERAPY
}}
| This area was generated with Dilib version V0.6.31. |  |